Apellis Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cedric Francois
- Full Time Employees
- 705
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Fifth Avenue Waltham MA United States of America 02451
- IPO Date
- Nov 9, 2017
- CIK
- 0001492422
- Website
- apellis.com
- Similar Companies
- Business
- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) is a commercial-stage global biopharmaceutical company focused on developing and commercializing targeted C3 therapies for complement-driven diseases in areas including hematology, ophthalmology, nephrology, and neurology; its core products comprise EMPAVELI (pegcetacoplan injection for subcutaneous use), approved for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and for adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria, Aspaveli (pegcetacoplan for subcutaneous use), the ex-U.S. brand equivalent of EMPAVELI approved for PNH, and SYFOVRE (pegcetacoplan injection for intravitreal use), indicated for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Founded in 2009 and headquartered in Waltham, Massachusetts, the company operates in the United States, Europe, Switzerland, and other international markets through commercialization rights and partnerships; it maintains systemic pegcetacoplan rights worldwide and worldwide intravitreal rights for its GA program. Recent developments include the U.S. FDA approval of EMPAVELI label expansion for C3G and IC-MPGN in 2025 with supportive Phase 3 VALIANT data demonstrating proteinuria reduction, a capped royalty purchase agreement with Sobi providing up to $300 million upfront ($275 million cash plus milestones) in exchange for 90% of ex-U.S. Aspaveli royalties to bolster its balance sheet amid pursuit of profitability, ongoing SYFOVRE market leadership at 60% share in GA treatment, and collaborations such as with Beam Therapeutics for gene editing technologies targeting neonatal Fc receptor and with Genpharm for Middle East/North Africa commercialization of intravitreal pegcetacoplan.
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Are CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders?
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of “Hold” by Analysts
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Here Are Thursday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Astra-Zeneca, Brinker, e.l.f. Beauty, Freeport-McMoran, Vale, Wingstop, Wix.com, and More
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week High – Should You Buy?
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boeing, Datadog, Disney, Formula One Group, Nike, Rivian, Rocket Lab, ServiceNow, and More